Biomarin Pharmaceutical Inc. - Registered Shares
BMRN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.29B
Close$
$96.68
65.8% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details
Target Price by Analysts
65.8% upsideBiomarin Pharmaceutical - Registered Shares Target Price DetailsInsider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $11.29 Billion |
|---|---|
| Enterprise Value | $14.75 Billion |
| Earnings per Share | $1.82 |
| Beta | 0.22 |
| Outstanding Shares | 193,590,000 |
Return
| Return on Equity | -0.31% |
|---|---|
| Return on Assets | -0.17% |
| Return on Invested Capital | 0.24% |
Valuation & Multiples
| P/E Ratio | -622.56 |
|---|---|
| PEG | -207.85 |
| Price to Sales | 3.24 |
| Price to Book Ratio | 1.82 |
| Enterprise Value to Revenue | 4.03 |
| Enterprise Value to EBIT | 619.12 |
| Enterprise Value to Net Income | -772 |
| Total Debt to Enterprise | 0.28 |
| Debt to Equity | 0.67 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 2, 2026
EPS
$0.23
Est. -$0.05Revenue
$1.02 B
Est. $1.02 BNext Earnings Call
Expected Date
February 22, 2027
EPS Estimate
$0.82
Consensus analyst estimateRevenue Estimate
$1.09 B
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.65, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.6494▲ 27.96% |
|---|---|
| Total Calls | 46,196▼ 97.38% |
| Total Puts | 30,000▼ 95.40% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 11.65%▼ 89.69% |
|---|---|
| Total Invested | $1.35B▼ 87.96% |
| Investors Holding | 254▼ 334.00% |
About Biomarin Pharmaceutical Inc.
3,221 employees
CEO: Jean-Jacques Bienaime
BioMarin Pharmaceutical Inc. specializes in the development and commercialization of therapeutic solutions for individuals grappling with severe and life-threatening rare diseases. Its array of market-ready products features Vimizim, an ...